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Abstract
The public health burden caused by methicillin-resistant Staphylococcus aureus (MRSA) infections is now widely recognized, and is a cause
of public alarm. Effective MRSA risk management in the healthcare system as well as in the community should rely on accurate detec-
tion of reservoirs and sources of transmission, as well as on close monitoring of the impact of interventions on disease incidence and
bacterial dissemination. MRSA carrier screening and disease surveillance, coupled with molecular typing, are key information tools for
integrated MRSA control and individual risk assessment. These tools should be tailored to the distinct needs of local interventions and
national prevention programmes. Surveillance schemes should primarily inform local staff and serve as quality assurance about MRSA
risk management. New technologies, including the use of selective culture media and real-time PCR assays, allow faster detection of
MRSA carriers upon admission or during stay in healthcare institutions. More research is needed to ascertain their cost-effectiveness
for MRSA control. Likewise, tremendous progress has been made concerning molecular typing methods, with optimization and stan-
dardization of sequence-based technologies offering broad applicability and high throughput. However, no single S. aureus typing method
is yet providing fully reliable information within the range of discrimination needed for public health action. Further reﬁnement of geno-
typing methods and international harmonization of surveillance and typing schemes must be achieved to facilitate global MRSA control.
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Introduction
The magnitude of the health threat caused by antibiotic-
resistant bacteria in general and methicillin-resistant Staphylo-
coccus aureus (MRSA) in particular is increasingly appreciated
by public health agencies, the media, and governments [1,2].
Reports on the increasing incidence of infections caused by
community-acquired MRSA (CA-MRSA) and healthcare-asso-
ciated MRSA in many parts of the world have raised concern
about the failure of current control strategies. On the other
hand, several countries have reported persistently low or
decreasing incidence rates of MRSA disease. Many guidelines
produced by national professional bodies and health agencies
have advocated a range of strategies to contain the transmis-
sion of MRSA in healthcare facilities and the community;
these combine improvement of basic hygiene with targeted
surveillance and control measures based on screening indi-
viduals for carriage of MRSA [3]. Controversy exists about
their effectiveness and general applicability.
In this consensus statement, practitioners from different
European countries with experience in the surveillance and
control of MRSA have appraised the best strategies available
and outlined the criteria that may help in selecting and apply-
ing laboratory and epidemiological tools for MRSA detection,
surveillance, and typing. Readers are referred to other
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sources for detailed descriptions of the evidence base, where
available.
Active Surveillance of MRSA Carriers
Active surveillance (or screening) for MRSA carriers is the
systematic use of microbiological tests able to detect muco-
cutaneous carriage of MRSA by individuals without clinical
infection. This is an essential component of MRSA control
strategies in acute-care hospitals, and it is also potentially
useful in other healthcare facilities, in both MRSA-endemic
and low-incidence settings. This is based on the well-estab-
lished fact that more than half of the reservoir of MRSA-col-
onized patients admitted to hospitals will go undetected by
sampling of clinical specimens for routine diagnostic testing,
unless swab samples of the nares, skin, wounds and, possibly,
rectum and throat are tested speciﬁcally for MRSA using
selective culture and/or DNA ampliﬁcation methods
[3,4].These MRSA carriers may act as a source of transmis-
sion to other patients in the facility, unless they are readily
identiﬁed and cared for with additional isolation precautions.
Mathematical modelling supports the view that, without
active carrier screening, implementation of isolation and car-
rier decolonization precautions will fail to decrease transmis-
sion of MRSA in acute-care hospitals [5,6]. Moreover, during
outbreaks, admission screening differentiates ‘imported cases’
(positive culture/PCR within 48 h after admission) from new
cases of hospital-acquired colonization or infection (ﬁrst
positive culture/PCR more than 48 h after admission). This
differentiation is essential for monitoring of the effect of con-
trol measures.
In addition, screening of MRSA or S. aureus carriage
before planned surgery may be beneﬁcial to the individual
patient in reducing the risk of surgical site infection by allow-
ing targeted S. aureus preoperative topical decolonization
and/or perioperative prophylaxis [7]. Active surveillance of
MRSA also provides information about colonization status,
which may help clinicians to choose appropriate antibiotic
therapy in cases of infection.
Several conditions must be met to effectively implement
active surveillance of MRSA at the hospital level. First, it
should be driven by need, in other words, evidence that
MRSA transmission and/or surgical site infection occurs
locally in spite of good compliance by healthcare staff with
standard precautions such as hand hygiene and prophylaxis.
Second, the extent of active surveillance according to
department or type of patient should be adjusted to the
patient isolation capacity and the effectiveness in controlling
spread and preventing infection. The effectiveness of active
surveillance should be periodically checked by local risk
assessment.
An unresolved aspect is the decision about who should
be screened upon hospital admission. Options range from
universal screening (performed for all admitted patients) to
screening of a selection of high-risk groups. Mathematical
models suggest that universal screening would be most effec-
tive [5,8]. Indeed, some recent observational studies have
documented a major reduction in the incidence of MRSA
infection after the introduction of universal surveillance and
isolation of carriers in all cases of admission to tertiary-care
hospitals [9] or to surgical wards [10]. However, selective
screening is the usual practice, for reasons of cost and logis-
tics. Which, then, are the particular patient groups or care
settings that can be proposed for screening? Single-centre
and multicentre studies have identiﬁed risk factors that pre-
dict MRSA carriage upon admission. They include older age,
transfer from or previous stay in another hospital, admission
from a long-term-care facility, and underlying health condi-
tions such as wounds or diabetes [11]. By application of a
multi-criteria risk score, a higher yield of positive tests can
be achieved, but with a sensitivity below c. 80%. However,
this approach is difﬁcult to implement routinely because
of the limited compliance of nursing staff in performing
the extensive review of medical history required to assess
the risk proﬁle of each individual before taking surveillance
samples.
Another pragmatic approach that has been widely ﬁeld-
tested is to target patient-care services and departments
caring for patients at high risk of MRSA transmission and/
or invasive infections. Targeted patient groups include
those in adult and neonatal intensive-care, dialysis, cardio-
thoracic, vascular and orthopaedic surgery units. In high-
risk units such as intensive care, where the pretest
probability of MRSA carriage can reach 10–30% of admis-
sions, the strategy of pre-emptive isolation and screening
of all patients followed by release from isolation after
negative test ﬁndings for MRSA (also called the ‘guilty until
proven innocent’ strategy) can be considered. In this set-
ting, the use of a rapid screening test such as PCR offers
clear advantages, although, when it was implemented in
two intensive-care units, somewhat discrepant results were
obtained [12].
In any event, a local policy of admission screening for
MRSA should be developed by the infection control team,
based on the identiﬁcation of local high-risk units and patient
groups. Compliance with screening and isolation policies
must be audited. Adequate compliance depends heavily on
continuing education of all involved healthcare workers, as
well as on the regular feedback of results.
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Infections caused by CA-MRSA strains are currently far
less common in Europe than in North America. To maintain
this low incidence, vigilance must be maintained to promptly
identify cases of CA-MRSA carriage and infection as they
occur. This requires more extensive microbiological testing
of skin and soft tissue infections in both general and emer-
gency-care practice. MRSA screening upon hospital admission
should be considered for patients transferred from foreign
hospitals or those who have travelled to a foreign country.
This is routine practice, and forms an integral part of
national MRSA control policy in low-incidence countries such
as The Netherlands and Scandinavia. When Panton–Valentine
leukocidin (PVL)-producing MRSA strains are detected, fur-
ther contact tracing is warranted to identify and decolonize
MRSA carriers and individuals with skin infections among
family and close social contacts. This approach has been
found to limit the community spread of imported PVL-pro-
ducing MRSA strains [13,14]. Opinions vary as to whether
such screening and contact tracing should be performed in
every sporadic case of PVL-producing MRSA infection/coloni-
zation or only in those producing severe invasive infection
or clusters of disease. More research is needed in this area.
Finally, ‘livestock-associated’ strains of MRSA, most fre-
quently belonging to the ST398 clonal lineage, have recently
emerged in several countries, including France, The Nether-
lands, Denmark, Germany, and Belgium. Individuals living
in these countries and who are frequently exposed to farm
animals such as pigs and calves, because of either their
professional occupation or their place of residence, should
also be considered to be at high risk for MRSA carriage and
eligible for screening upon admission to healthcare facilities
[15,16].
In addition to active surveillance for MRSA upon admis-
sion, further surveillance of patients during MRSA outbreaks,
or, when a single case is detected in low-incidence settings,
periodic (e.g. weekly) screening of patients in the ward or
institution concerned can be useful to rapidly identify, isolate
and/or decontaminate patients newly colonized by MRSA.
Furthermore, post-admission screening is essential to deter-
mine the transmission epidemiology of MRSA among patients
transferred within or between wards and facilities.
The issue of screening for MRSA carriage among health-
care workers is ethically sensitive, because positive results
may jeopardize an individual’s ability to safely perform clin-
ical duties and may oblige them to undergo medical treat-
ment. In low-incidence countries, screening of all staff in
contact with a case of MRSA infection or colonization,
and decolonization of all carriers, is part of the standard
‘search-and-destroy’ policy, the value of which has been
amply demonstrated in protecting these healthcare systems
against the MRSA pandemic. In endemic settings, where
MRSA cases are encountered by clinical staff on a daily
basis, this is impracticable. Furthermore, in the vast major-
ity of cases, carriage by healthcare workers is transient,
and spontaneously resolves within hours. Nevertheless,
outbreaks can be initiated or maintained by staff members
who become chronic carriers and ‘human disseminators’.
Such a phenomenon usually occurs in people who suffer
from skin disease or upper respiratory tract inﬂammation.
Surgical and intensive-care personnel are the most fre-
quently involved [17]. When epidemiological and molecular
typing evidence points to a common source for a cluster
of deep-seated infections (e.g. of surgical sites), it may be
useful to screen staff and treat chronic carriers until
MRSA is eradicated.
Laboratory Tools for MRSA Screening
The optimal procedures for screening for MRSA mucocuta-
neous carriage are currently under investigation. These
include the choice of the anatomical sites to be sampled, the
sampling method, and the laboratory methods for processing
and testing of the samples. These aspects are discussed
below, and key areas for research are outlined.
Screening for MRSA carriage is generally performed by
swabbing the anterior nares or multiple superﬁcial sites,
including nares, throat, and perineum [4]. Additional samples
may be taken from the rectum, sputum of ventilated patients,
wounds, and/or catheter insertion sites. Nasal screening is
reported to have a sensitivity of over 80%, which can
increase to 95% when additional sites are screened, although,
in some series, screening in up to one-third of carriers was
restricted to either the throat or rectum.
Sterile cotton or Dacron swabs can be used, and should
be placed in a buffered medium for transportation to the lab-
oratory. The use of liquid rather than gel transport medium
may increase the recovery of bacteria from the swab, and
the sensitivity of detection.
Conventional MRSA detection methods rely on selective
culture in liquid and/or on solid media. Recent chromogenic,
cefoxitin-based selective agar media have demonstrated
superior selectivity, speciﬁcity and faster time to detection
for MRSA screening than non-chromogenic media [4], and
several chromogenic commercial media have performed well
in clinical evaluations [18]. MRSA is detected in 20–48 h with
most of these media, and negative results are usually reliable
at 24 h. The use of a pre-enrichment step in selective broth
medium increases the sensitivity of these media by 15–30%,
but increases the cost and delays the results by an additional
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18–24 h. Therefore, the practical value and cost-effectiveness
of using an enrichment step needs further study.
Rapid (same-day) MRSA detection is potentially relevant
for patient management [19]. It can be achieved by using sev-
eral commercial or in-house nucleic acid ampliﬁcation and
hybridization assays [18–20].
Although these ‘rapid’ methods offer a turn-around time
to results ranging between 75 min and 6 h, one should keep
in mind that other delays in the diagnostic process comprise
time from admission to sampling, from sample collection to
laboratory reception, from laboratory reception to testing,
and from test result production to ward reporting and imple-
mentation of isolation precautions. Pre-analysis and post-anal-
ysis steps typically make these rapid test results available for
action, at best, within 24 h after admission, or later if testing
is not performed 7 days a week and 24 hours a day [12]. Ide-
ally, these tests should be accurate, rapid (<2 h process
time), random access, robust, accessible to laboratory work-
ers with basic skills, and affordable for high-volume use.
Recent health technology assessment studies showed the
promising performance of several commercial tests [18–20].
In addition to validation of test robustness and diagnostic
accuracy, future health technology assessment research
should establish the added medical value of these molecular
detection systems, such as decreased MRSA nosocomial
transmission and improved patient outcome, as compared
with best-in-class conventional screening methods.
The need to measure this beneﬁt by performing multicen-
tre, national intervention trials in countries and hospitals
with low, medium and high MRSA prevalence levels must be
stressed. These trials should be controlled by comparing
multiple intervention arms based on PCR vs. conventional
testing, including, where appropriate, the use of pre-emptive
isolation measures. Studies should preferably follow a clus-
ter-randomized, cross-over design. Adherence to protocol
should be closely monitored, and appropriate adjustments
should be made for key confounding factors, including other
control measures, hand hygiene compliance, colonization
pressure, and antibiotic exposure. Relevant primary out-
comes are incidence rates of nosocomial MRSA acquisition
(as deﬁned by temporal sequence after admission and molec-
ular typing evidence) and incidence rates of nosocomial
MRSA infection. Secondary outcomes of interest include
length of patient stay, days of isolation, and days of antibiotic
therapy. An evaluation of cost-effectiveness should also be
part of these investigations. However, should any of the
rapid MRSA detection assays prove to be cost-effective, the
local beneﬁt would still need to be further validated by inter-
rupted time-series analysis before and after introduction into
routine practice.
The results of two well-designed and strictly controlled
trials have been published [21,22] since the consensus con-
ference being reported here took place. Unfortunately, both
studies concluded that there is a lack of demonstrable bene-
ﬁt of rapid PCR detection of MRSA upon admission to medi-
cal and surgical wards, in a tertiary-care centre in England in
one study, and in patients undergoing clean surgery in a ter-
tiary-care hospital in Switzerland in the other. More inter-
vention studies of this quality are needed to ascertain the
cost-effectiveness of rapid MRSA screening in relevant
patient populations and healthcare systems.
Surveillance Methods at Local, National
and International Levels
The most robust and clinically relevant surveillance indica-
tors for monitoring MRSA control programmes are inci-
dence rates of community-acquired and hospital-acquired
infections. For the latter population, incidence of MRSA
bacteraemia is probably the most objective and readily
comparable indicator for longitudinal risk assessment, at
both local and multi-hospital levels. These indicators
must be monitored prospectively by adequately trained
personnel, using standard case deﬁnitions and validated
microbiological test results.
The rate of MRSA bacteraemia is a clinically relevant qual-
ity indicator that is also sensitive to the other preventive
measures applied to intravenous catheter use, surgery, and
intensive care. However, the rate of MRSA bacteraemia is
inﬂuenced by many factors other than infection control,
including the case mix and the rate of transfer from other
institutions. Laboratory utilization rates should be measured
to adjust this indicator for potential ascertainment bias. The
relative frequency of MRSA among non-duplicate S. aureus
clinical isolates by specimen type is a more easily accessible
surrogate marker, and is used for international MRSA sur-
veillance by the EARSS programme. However, the absence of
a record of epidemiological factors to allow classiﬁcation into
the categories of community-onset, community-acquired and
hospital-acquired cases may obscure proper interpretation of
rates. Likewise, it would be desirable to adjust for the colo-
nization pressure by relating healthcare-associated MRSA
infection to the prevalence of MRSA carriage upon admis-
sion. Without universal admission screening, this is not gen-
erally applicable, but it can be attempted in special care
settings, such as critical-care units, where screening has
become standard practice.
From an operational standpoint, local surveillance
can make possible the estimation of the incidence rate of
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nosocomial MRSA acquisition (number of new cases of
MRSA colonization detected on day 3 (or later) of hospital
stay/1000 patient-days) as a sensitive indicator of control
measures. It can be further reﬁned by excluding from the
denominators all patients with a short duration of stay
(<48 h) and those already colonized upon admission. How-
ever, such an indicator is greatly affected by ascertainment
bias, unless extensive patient screening is performed upon
admission, during stay, and at discharge from the facility. A
surrogate marker for this indicator that has been used for
crude inter-hospital comparison is the counting of only new
cases detected after performance of clinical cultures.
It is essential that the results of these surveillance indica-
tors be fed back regularly to practitioners at ward level. Use
of multiple indicators and analysis methods is preferable.
Examples of feedback formats include root cause analysis of
single cases of MRSA bacteraemia, quarterly/yearly rates of
nosocomial MRSA acquisition and infection interpreted with
statistical process charts or temporal trend analysis, and
analysis of clusters of cases according to time, person, expo-
sure, and genotype.
Typing Tools for MRSA Outbreak
Investigation and Surveillance
An overview of the most popular S. aureus typing meth-
ods, with their respective strengths and weaknesses, is
shown in Table 1. Because S. aureus has a highly clonal
population structure, many different chromosomal markers
indexing polymorphism in coding or noncoding regions will
provide largely congruent classiﬁcations of isolates into
clonal lineages, albeit with differing levels of resolution,
depending on the number of loci analysed and their
molecular clocks. This is true for DNA restriction poly-
morphism as well as for variable number of tandem DNA
repeat data, inter-repeat element spacer polymorphism,
and single-nucleotide polymorphism (SNP) [21–25]. Multilo-
cus sequence typing, by indexing allelic polymorphism in
seven neutral housekeeping genes, is the reference method
for deﬁning the core genetic population structure of
S. aureus, which is dominated by a dozen major clonal
complexes and comprises several hundred clonal lineages
or sequence types (STs) [26]. However, for epidemiologi-
cal typing, MLST has only moderate discriminatory power,
and it remains too labour-intensive and costly for use as a
primary typing tool. In addition to deﬁning the bacterial
chromosomal background, additional molecular tests should
be applied to subtype the mobile methicillin resistance ele-
ment, called the staphylococcal chromosomal cassette mec
or SCCmec, which differentiates MRSA clones of common
ancestry but distinct epidemiological origin [27].
For over a decade now, pulsed-ﬁeld gel electrophoresis of
genomic macrorestriction fragments has been widely used
for local outbreak investigation and as part of typing systems
for long-term surveillance of MRSA infections at regional and
national levels. It is a highly discriminatory tool, for which
epidemiologically validated interpretation criteria have been
published for the investigation of local transmission of MRSA
strains and outbreak management [28]. However, it is
a technically demanding and low-throughput method, with
limited portability owing to technical challenges in achieving
interlaboratory comparability and standardization. In addition,
attribution of pulsed-ﬁeld gel electrophoresis clusters to
TABLE 1. Comparison of the main currently available methicillin-resistant Staphylococcus aureus molecular typing methods
Method Principle/target Strengths Weaknesses
Multilocus sequence
typing (MLST)
Sequence determination of allelic variants
of housekeeping genes
Phylogenetic structure
of core genome
Interlaboratory portability
Standard nomenclature
Limited discriminatory power
Low throughput
Cost
Macrorestriction pattern
analysis (PFGE)
Restriction polymorphism of the
whole chromosome
High discriminatory power Technically demanding
Slow
Limited interlaboratory portability
Multiple nomenclatures
spa-sequence typing Polymorphism of number and sequence of
repeat elements of the hypervariable gene
Rapid
High throughput
Interlaboratory portability
Standard nomenclature
Attribution of MLST STs by
BURP algorithm
Moderate discriminatory power
Misclassiﬁcation of particular STs
due to recombination/homoplasy
Rep-PCR typing Polymorphism in chromosomal inter-repeat
element spacers
Rapid
High throughput
Limited discriminatory power
No validated interpretation criteria
No standard nomenclature
Multilocus VNTR
analysis (MLVA)
Polymorphism in number of chromosomal
VNTR elements
Rapid
High throughput
Limited discriminatory power
No validated interpretation criteria
No standard nomenclature
PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type; VNTR, variable number of tandem DNA repeat.
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genetic lineages may be problematic, and some strains, such
as the ‘livestock-associated’ ST398 strains, are non-typeable
by standard protocols, owing to restriction site methylation.
The determination of sequence polymorphism in the vari-
able X region of the spa gene encoding the staphylococcal
surface protein A (spa sequence typing) has become the most
popular MRSA typing system. Its popularity is attributable to
its many practical advantages, including high throughput and
full portability of data, thanks to its absolute reproducibility,
which allows internet-based type assignment and comparison
with a worldwide database [29,30]. It has therefore become
one of the primary typing methods for regional and national
MRSA surveillance schemes. Nevertheless, this technique also
has limitations, which necessitate the use of additional tests
for reliable typing in some circumstances. Indeed, spa types
do not allow reliable inference of particular genetic ST lin-
eages (e.g. ST1, ST8, and ST80). In these cases, the use of
PCR for the analysis of additional markers, such as toxin and
antibiotic resistance genes located on clone-speciﬁc mobile
genetic elements, is needed for correct ST delineation and
assignment [23,30]. Repeat-based spa locus polymorphism is
subject to misclassiﬁcation bias, owing to both horizontal
DNA transfer and recombination (e.g. in ST239) and homo-
plasy (e.g. in ST5 subclones) [31].
Other high-throughput MRSA typing techniques include
rep-PCR typing and multilocus variable tandem repeat analysis
(MLVA). The former was shown to be variably discriminative
but poorly reproducible among laboratories when based on
in-house protocols [32]. A kit-based rep-PCR assay combined
with a commercial ﬁngerprint analysis platform (Diversilab;
Bacterial BarCodes, Houston, TX, USA) showed excellent
reproducibility but moderate discrimination, and remains
impeded by the lack of validated criteria for interpretation
and type nomenclature [33]. MLVA schemes share the rep-
PCR advantages of rapid turn-around times and high through-
put, but their discriminatory power depends on the number
and types of variable number of tandem DNA repeat/Staphy-
loccal interspersed repeat units (SIRUs) loci analysed. As with
rep-PCR, no standard MLVA protocol or international
nomenclature is yet available for type assignment.
Typing of SCCmec elements should be performed for multi-
centre surveillance and analysis of interhospital or interna-
tional MRSA strain transmission and evolution, especially
among the ST5, ST8 and ST398 lineages, which harbour a
diversity of cassette types and subtypes. Several methods,
which rely either on PCR mapping of cassette elements (such
as the ccr complex, mec complex and J regions) or on sequence
determination of an internal fragment of the recombinase gene
ccrB, are available for this purpose. A combination of these
two approaches is recommended for reliable typing.
Finally, SNP detection methods offer an efﬁcient alterna-
tive to the above-mentioned typing methods. These methods
have been developed for rapid identiﬁcation of major
S. aureus clonal complexes and STs as well as for detailed
discrimination of regionally emerging MRSA subclones [31].
Additional mutation discovery studies in different S. aureus
lineages should allow the development of a standard hierar-
chical SNP catalogue that could be used for high-throughput,
scalable-resolution SNP typing systems. In the meantime,
PCR-based or microarray-based detection of clone-speciﬁc
SNPs, genes or genomic islands can be useful for rapid iden-
tiﬁcation of epidemiologically important MRSA clones (such
as ST1, ST80, ST8-‘USA300’, and ST398).
Conclusion
MRSA carrier screening, surveillance and molecular typing
are pivotal information tools for integrated MRSA control
programmes. New technologies offer tremendous potential
for more effective and timely interventions. There is an
urgent need for health professionals, in vitro diagnostics com-
panies and policy-makers to work together to assess the
cost-effectiveness of these tools for safer care of patients
and protection of the public against the tide of MRSA. In
addition, greater international harmonization of surveillance
and typing schemes is needed to facilitate cooperation in an
effort to control the MRSA pandemic.
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